Kenvue Inc. (NYSE:KVUE) Position Decreased by Rudius Management LP

Rudius Management LP lessened its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 80.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 251,894 shares of the company’s stock after selling 1,060,000 shares during the quarter. Kenvue comprises 1.2% of Rudius Management LP’s investment portfolio, making the stock its 6th largest position. Rudius Management LP’s holdings in Kenvue were worth $5,826,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Riverview Trust Co bought a new position in Kenvue during the third quarter valued at approximately $30,000. Ashton Thomas Securities LLC bought a new position in shares of Kenvue during the third quarter valued at about $35,000. Deseret Mutual Benefit Administrators increased its holdings in shares of Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after buying an additional 651 shares during the period. Studio Investment Management LLC increased its holdings in shares of Kenvue by 52.1% in the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after buying an additional 845 shares during the period. Finally, Brooklyn Investment Group bought a new stake in shares of Kenvue in the 3rd quarter valued at about $71,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE KVUE opened at $24.12 on Wednesday. The stock has a market capitalization of $46.24 billion, a PE ratio of 43.85, a P/E/G ratio of 2.20 and a beta of 1.36. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The business has a 50 day simple moving average of $22.87 and a two-hundred day simple moving average of $20.92. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Kenvue’s revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.31 earnings per share. On average, research analysts predict that Kenvue Inc. will post 1.07 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on KVUE shares. Bank of America lifted their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, October 22nd. JPMorgan Chase & Co. lifted their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada cut shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research report on Tuesday, September 24th. Piper Sandler boosted their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. Finally, Jefferies Financial Group began coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price for the company. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $22.64.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.